Thymopentin (TP5), an immunomodulatory peptide, suppresses proliferation and induces differentiation in HL-60 cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1763, Issue 10, 2006, Pages 1059-1066

  Fan, Ying zhe ^a   Chang, Hui ^a   Yu, Ye ^a   Liu, Jing ^a,b   Zhao, Li ^a,c   Yang, Ding jian ^a   Wang, Rui ^a  

^a North West Normal University   (China)

^b GANSU PROVINCIAL HOSPITAL   (China)

^c LANZHOU UNIVERSITY   (China)

Author keywords

Chemotherapeutic agent; Differentiation; HL 60; Proliferation inhibition; Thymopentin

Indexed keywords

ATROPINE; THYMOPENTIN; TUBOCURARINE CHLORIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINEAGE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG EFFECT; DRUG MECHANISM; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; LEUKEMIA; LEUKEMIA CELL; NUCLEOLUS; OBSERVATION; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD14; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HL-60 CELLS; HUMANS; NITROBLUE TETRAZOLIUM; PEPTIDES; SILVER STAINING; THYMOPENTIN;

EID: 33749058297     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2006.07.004     Document Type: Article

References (36)

1. Campbell M.J., Reddy G.S., and Koeffler H.P. Vitamin D3 analogs and their 24-Oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects. J. Cell. Biochem. 66 (1997) 413-425
2. Novichenko N., Konno S., Nakajima Y., Hsieh T.C., Xu W., Turo K., Ahmed T., and Chiao J.W. Growth attenuation in a human prostate cell line mediated by a phorbol ester. Proc. Soc. Exp. Biol. Med. 209 (1995) 152-156
3. Liu L., Shack S., Stetler-Stevenson W.G., Hudgins W.R., and Samid D. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J. Invest. Dermatol. 103 (1994) 335-340
4. Samid D., Shack S., and Myers C.E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest. 91 (1993) 2288-2295
5. Welsh J. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. Biochem. Cell. Biol. 72 (1994) 537-545
6. Li C.J., Wang C., and Pardee A.B. Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Res. 55 (1995) 3712-3715
7. Breitman T.R., Selonick S.E., and Collins S.J. Induction of differentiation of the human promyelocytic leukemia cell line HL-60 by retinoic acids. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 2936-2940
8. Collins S.J., Ruscetti F.W., Gallagher R.E., and Gallo R.C. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc. Natl. Acad. Sci. U. S. A. 75 (1978) 2458-2462
9. Collins S.J. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 70 (1987) 1233-1244
10. Bodey B., Bodey Jr. B., Siegel S.E., and Kaiser H.E. Review of thymic hormones in cancer diagnosis and treatment. Int. J. Immunopharmacol. 22 (2000) 261-273
11. Singh V.K., Biswas S., Mathur K.B., Haq W., Garg S.K., and Agarwal S.S. Thymopentin and splenopentin as immunomodulators, current status. Immunol. Res. 17 (1998) 345-368
12. Fan Y.Z., Chang H., Yu Y., Liu J., and Wang R. Thymosin α1 suppresses proliferation and induces apoptosis in human leukemia cell lines. Peptides 27 (2006) 2165-2173
13. Solmajer T. Design of a novel thymopoietin analogue based on conformational analyses. Drugs Des. Deliv. 6 (1990) 213-221
14. Goldstein G., Scheid M.P., Boyse E.A., Schlesinger D.H., and Van Wauwe J. Synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science 204 (1979) 1309-1310
15. Sundal E., and Bertelletti D. Management of viral infections with thymopentin. Arzneimittelforschung 44 (1994) 866-871
16. Smetana K., Jiraskova I., Perlaky L., and Busch H. The silver reaction of nucleolar proteins in the main structural compartments of ring-shaped nucleoli in smear preparations. Acta. Histochem. 101 (1999) 167-183
17. Okano T., Nakagawa K., Kubodera N., Ozono K., Isaka A., Osawa A., Terada M., and Mikami K. Catalytic asymmetric syntheses and biological activities of singly dehydroxylated 19-nor-1a,25-dihydroxyvitamin D3 A-ring analogs in cancer cell differentiation and apoptosis. Chem. Biol. 7 (2000) 173-184
18. Eugenia Riveiro M., Shayo C., Monczor F., Fernandez N., Baldi A., De Kimpe N., Rossi J., Debenedetti S., and Davio C. Induction of cell differentiation in human leukemia U-937 cells by 5-oxygenated-6,7-methylenedioxycoumarins from Pterocaulon polystachyum. Cancer Lett. 210 (2004) 179-188
19. Baehner R.L., and Nathan D.G. Quantitative nitroblue tetrazolium test in chronic granulomatous disease. N. Engl. J. Med. 278 (1968) 971-976
20. Lucas D.L., Tanuma S., Davies P.J., Wright D.G., and Johnson G.S. Maturation of human promyelocytic leukemia cells induced by nicotinamide: evidence of a regulatory role for ADP-ribosylation of chromosomal proteins. J. Cell. Physiol. 121 (1984) 334-340
21. Gimonet D., Grailhe R., Coninx P., Antonicelli F., Haye B., and Liautaud-Roger F. Functional role of nicotinic acetylcholine receptors in apoptosis in HL-60 cell line. Eur. J. Pharmacol. 482 (2003) 25-29
22. Kansas G.S., Muirhead M.J., and Dailey M.O. Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. Blood 76 (1990) 2483-2492
23. Schulze-Forster K., Eckert K., and Maurer H.R. The thymus extract thymex-L potentiates the retinoic acid-induced differentiation of the human myeloid leukemia cell line HL-60. Biochim. Biophys. Acta 1265 (1995) 110-116
24. Gonser S., Crompton N.E., Folkers G., and Weber E. Increased radiation toxicity by enhanced apoptotic clearance of HL-60 cells in the presence of the pentapeptide thymopentin, which selectively binds to apoptotic cells. Mutat. Res. 558 (2004) 19-26
25. Trere D., Pession A., and Derenzini M. The silver stained proteins of interphasic nucleolar organizer regions as a parameter of cell duplication rate. Exp. Cell Res. 184 (1989) 131-157
26. Koda M., Murate T., Wang S., Ohguchi K., Sobue S., Ikeda M., Tamiya-Koizumi K., Igarashi Y., Nozawa Y., and Banno Y. Sphingosine kinase 1 is involved in dibutyryl cyclic AMP-induced granulocytic differentiation through the upregulation of extracellular signal-regulated kinase, but not p38 MAP kinase, in HL60 cells. Biochim. Biophys. Acta 1733 (2005) 101-110
27. Nishinaka T., Fu Y.H., Chen L.I., Yokoyama K., and Chiu R. A unique cathepsin-like protease isolated from CV-1 cells is involved in rapid degradation of retinoblastoma susceptibility gene product, RB, and transcription factor SP1. Biochim. Biophys. Acta 1351 (1997) 274-286
28. Bartek J., Bartkova J., and Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp. Cell Res. 237 (1997) 1-6
29. Sachs L. Control of normal differentiation and the phenotypic reversion of malignancy in myeloid leukemia cells. Nature. 274 (1978) 535-539
30. 2D3 and its 20-epi analog integrates clonal expansion, maturation and apoptosis during HL-60 cell differentiation. Mol. Cell. Endocrinol. 149 (1999) 169-183
31. Gimonet D., Grailhe R., Coninx P., Antonicelli F., Haye B., and Liautaud-Roger F. Functional role of nicotinic acetylcholine receptors in apoptosis in HL-60 cell line. Eur. J. Pharmacol. 482 (2003) 25-29
32. Villiger Y., Szanto I., Jaconi S., Blanchet C., Buisson B., Krause K.H., Bertrand D., and Romand J.A. Expression of an alpha7 duplicate nicotinic acetylcholine receptor-related protein in human leukocytes. J. Neuroimmunol. 126 (2002) 86-98
33. Gonser S., Weber E., and Folkers G. Peptides and polypeptides as modulators of the immune response: thymopentin-An example with unknown mode of action. Pharm. Acta Helv. 73 (1999) 265-273
34. Cascinelli N., Belli F., Mascheroni L., Lenisa L., and Clemente C. Evaluation of clinical efficacy and tolerability of intravenous high dose thymopentin in advanced melanoma patients. Melanoma Res. 8 (1998) 83-89
35. Recchia F., Sica G., De Filippis S., Rosselli M., Pompili P., Saggio G., and Rea S. Chemo-immunotherapy in advanced head and neck cancer. Anticancer Res. 19 (1999) 773-777
36. Gallo F., Morale M.C., Sambataro D., Farinella Z., Scapagnini U., and Marchetti B. The immune system response during development and progression of carcinogen-induced rat mammary tumors: prevention of tumor growth and restoration of immune system responsiveness by thymopentin. Breast Cancer Res. Treat. 27 (1993) 221-237